Smoking is the top cause of death among lifestyle habits and continues to affect more than one billion people around the world. The current gold standard for smoking cessation is a combination of pharmacological and behavioural approaches. In March 2017, the National Addictions Management Service, Singapore, initiated a smoking cessation programme that combined the pharmacological treatment options of either nicotine replacement therapy, bupropion or varenicline with individual counselling to achieve optimal results. Treatment is customised to the individual based on demographics, individual preferences, cost considerations, and history of chronic medical or psychiatric ailments. After more than 1.5 years of running this programme, we share the lessons learnt.
INTRODUCTION
While healthcare efforts in Singapore have lately been focused on the prevention and treatment of diabetes mellitus, a small but important national centre has been working on another important issue: smoking. Smoking is perhaps the top cause of death among lifestyle habits and continues to affect more than one billion people around the world.
(1) 13.3% of the adult population in Singapore smoke, a prevalence that has remained relatively constant from 13 .6% in 2007. (2) A recent landmark meta-analysis concluded that even one stick of cigarette a day contributes to a substantially increased risk of cardiovascular morbidity. (3) Hence, even
if not all recorded smokers are heavy smokers, the healthcare burden can be quite substantial.
NICOTINE, THE SOURCE OF ADDICTION
Nicotine is a highly addictive chemical due to its characteristics: it readily crosses the blood brain barrier and has a quick onset of action with a short half-life. This chemical in cigarette smoke sustains the addiction to cigarettes, while the inhalation route further facilitates the direct delivery of nicotine to the brain. Over time, tolerance to nicotine develops, resulting in unpleasant withdrawal symptoms when plasma nicotine levels fall.
Other agents apart from cigarettes carry nicotine and tobacco. In the local context, beedi, shisha (banned in November 2014) and cigars are other modes of smoking. All these methods deliver nicotine, with cigarettes in particular having the risk of delivering more than 7,000 other chemicals, at least 69 of which are known carcinogens. (5) Why then do people continue to smoke despite such health risks? The answer pertains to the nicotine addiction that hijacks the reward centres of the brain. Once an addiction is formed, it becomes infinitely much harder to quit any habit. The brain's neurochemical pathways are rewired and help is therefore needed to fight the addiction. 
Through a combination of NRT or medications with behavioural approaches, any attempt to quit has a 19.0%-55.2% rate of success at the end of one year. (9) (10) (11) (12) Another study estimated the effectiveness of various pharmacologic therapies combined with behavioural therapy on smoking cessation to be 23.0% (bupropion), 32.5% (varenicline) and 52.8%
(NRT), with an overall success rate of 35.0%. 
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The piCO Smokerlyzer defines CO levels in non-smokers as 0-6 ppm, low-dependence smokers as 7-15 ppm and strongly addicted smokers as over 15 ppm. (16) This is followed by a thorough clinical history-taking and physical assessment. The clinical history focuses on elucidating the chronicity of the smoking; the number of cigarettes smoked per day; any history of quit attempts; any withdrawal symptoms during previous quit attempts; any previous treatment for smoking cessation; triggers for smoking; the presence of If NRT is chosen as the modality of treatment, its amount is titrated according to the current levels of smoking. It is recommended that both a short-and a long-acting nicotine replacement product are used simultaneously. The long-acting nicotine product (patch) helps in relieving baseline cravings for nicotine, while the short-acting product (gum/lozenge) helps with breakthrough cravings. The patient is also educated on the proper use of the nicotine Page 5 of 9 gum, as frequent misuse results in the swallowing of nicotine rather than absorption through the buccal mucosa. The most important aspect of NRT is the need for accurate dosing, as underdosing results in treatment failure. The practical aspect of cost also matters; optimal dosage sometimes cannot be instituted due to the high cost of NRT. Hence, when patients are very heavy smokers, it is more economical to consider bupropion or varenicline.
Furthermore, NRT is not as effective in women smokers due to their more rapid metabolism of nicotine.
Titration of bupropion or varenicline treatment is relatively straightforward, as it is not dependent on the patient's level of smoking. The usual dose for bupropion is 150 mg once a day for three days, increasing to 150 mg twice a day and continued for 7-12 weeks. (18) The standard regimen for varenicline is 0.5 mg per day for the first three days, followed by 0.5 mg twice daily for four days and 1.0 mg twice daily from Day 8 onwards. (13) However, as these are pharmacological agents, there is a potential for untoward side effects and drug-drug interactions. This is different from NRT, in which the active ingredient nicotine is already found in cigarette smoke. Hence, patients with a history of seizures, eating disorders and certain psychiatric ailments may not be suitable for bupropion. Similar considerations exist for varenicline. Between the two treatments, bupropion is very much cheaper, as generic formulations are already available. However, success rates for smoking cessation are better for varenicline. (18) Counselling is part of our treatment process and is aimed at behavioural change. Our be seen by their attending doctor every month. For each review visit, we work on progressive improvement using modest goals, for example, a 50% reduction in the level of smoking for heavy smokers compared with the last session. This is opposed to the current approach elsewhere, whereby patients do not usually have any follow-up sessions after a brief consultation with a pharmacist. We have learnt that a consistent, steady approach is more effective than a pressing need for immediate abstinence.
LESSONS LEARNT
After more than 1. patients who were not due for their three-month follow-up, we found that 49 (69.0%) of the remaining 71 patients defaulted on their follow-up appointment. Of the 22 patients who completed the three-month follow-up, 6 (27.3%) stopped smoking completely, while another 13 (59.1%) reduced the number of cigarettes smoked. This is comparable with the other local smoking cessation services with published outcomes. (19) (20) (21) Currently, we are in the process of extending smoking cessation services to the whole of IMH, as smoking is quite prevalent among patients with mental illness (PMIs) and contributes to the increased morbidity and mortality of our patients. We hope that the same approach would be effective. With the worldwide prevalence of smoking in PMIs being disproportionately higher than that in the general population, (22) (23) it is important to lower the health inequality experienced as a result of smoking.
